<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; products</title>
	<atom:link href="http://www.tapanray.in/tag/products/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Focus More To Create Patient-Perceived Value of Brand Outcomes</title>
		<link>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-more-to-create-patient-perceived-value-of-brand-outcomes</link>
		<comments>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/#comments</comments>
		<pubDate>Mon, 01 Nov 2021 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2021]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[age]]></category>
		<category><![CDATA[brand outcomes]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[Complex]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[criticality]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[group]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[older]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perceived]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10603</guid>
		<description><![CDATA[Healthcare providers, including many drug companies aim to create a beneficial effect on patients with their respective products and services. However, and more importantly, these benefits need to be such that recipients are able to sense, feel, and perceive as &#8230; <a href="http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Challenges For Brand Launch Success In The New Normal</title>
		<link>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-challenges-for-brand-launch-success-in-the-new-normal</link>
		<comments>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 08 Feb 2021 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[factors]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[orchestrators]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patient-centric]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pivotal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[primary care]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10407</guid>
		<description><![CDATA[The drug manufacturers’ life blood to drive business growth has always been successful new product launch. However, this task has always remained a tough challenge to crack, since last so many years for various reasons. According to McKinsey &#38; Company: “About two-thirds of drug &#8230; <a href="http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Coronavirus Outbreak: Drug Shortage, Treatment And Unease – A Review</title>
		<link>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review</link>
		<comments>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/#comments</comments>
		<pubDate>Mon, 09 Mar 2020 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[26 drugs]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[bullet]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[disruption]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Drug Shortage]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[hand]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[import ban]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[masks]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[N95]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[sanitizer]]></category>
		<category><![CDATA[serum Institute]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transmitted]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Unease]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9903</guid>
		<description><![CDATA[The Coronavirus outbreak has reached a &#8220;decisive point&#8221; and has &#8220;pandemic potential&#8221;, said the Director General of the World Health Organization (W.H.O), reportedly, on February 27, 2020, urging governments to act swiftly and aggressively to contain the virus. He further added, &#8220;We are &#8230; <a href="http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/coronavirus-outbreak-drug-shortage-treatment-and-unease-a-review/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Patient-Centricity: Emerging a C-Suite Role</title>
		<link>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-patient-centricity-emerging-a-c-suite-role</link>
		<comments>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/#comments</comments>
		<pubDate>Mon, 20 Aug 2018 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attributes]]></category>
		<category><![CDATA[C-suite]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[consistently]]></category>
		<category><![CDATA[CPO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[LEO]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pillars]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9110</guid>
		<description><![CDATA[Regardless of skepticism of many, the formidable power of physicians to take all treatment decisions for patients, is gradually getting moderated, globally. Although, its pace may vary from country to country. An increasing number of more informed patients are carving &#8230; <a href="http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Evolving Scenario of Non-Personal Promotion in Pharma Marketing</title>
		<link>http://www.tapanray.in/evolving-scenario-of-non-personal-promotion-in-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=evolving-scenario-of-non-personal-promotion-in-pharma-marketing</link>
		<comments>http://www.tapanray.in/evolving-scenario-of-non-personal-promotion-in-pharma-marketing/#comments</comments>
		<pubDate>Mon, 28 Sep 2015 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cash]]></category>
		<category><![CDATA[cocoon]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[cow]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[interactive]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mature]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[message]]></category>
		<category><![CDATA[monitor]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[NPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[practitioners]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[restricted]]></category>
		<category><![CDATA[specialists]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7102</guid>
		<description><![CDATA[In the Indian pharmaceutical industry, ‘Non-Personal Promotion (NPP)’ is gradually expected to assume much greater strategic importance than what it is today, if at all, in the overall strategic marketing ball game. This process would get hastened as and when &#8230; <a href="http://www.tapanray.in/evolving-scenario-of-non-personal-promotion-in-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/evolving-scenario-of-non-personal-promotion-in-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The ‘TINA Factor’: A Hotspot for Patented Drugs</title>
		<link>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-tina-factor-a-hotspot-for-patented-drugs</link>
		<comments>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/#comments</comments>
		<pubDate>Mon, 16 Dec 2013 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alternative]]></category>
		<category><![CDATA[Andre]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[foist]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TINA]]></category>
		<category><![CDATA[TPP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[virus]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4555</guid>
		<description><![CDATA[An article published in a global business magazine on December 5, 2013 mentioned that Marijn Dekkers, the CEO of Bayer AG reportedly has said at the Financial Times Global Pharmaceutical &#38; Biotech Conference held this month that: “Bayer didn’t develop its cancer drug, Nexavar (sorafenib) for &#8230; <a href="http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Humongous Pharma Corruption: China Ups The Ante&#8230;and India?</title>
		<link>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=humongous-pharma-corruption-china-ups-the-ante-and-india</link>
		<comments>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/#comments</comments>
		<pubDate>Mon, 23 Sep 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alcon]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[Apco]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[behind]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[biopharmaceuticals]]></category>
		<category><![CDATA[bribers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chases]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conducts]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[crack]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[Food]]></category>
		<category><![CDATA[Gan]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Lee]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[remain]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[Sino]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[Values]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3696</guid>
		<description><![CDATA[In the &#8216;pharma bribery&#8217; related scandal in China, many postulated that the Chinese Government has cracked down selectively on Multinational Corporations (MNCs) to extend unfair business advantages for its local players. Media reports of September 2013 indicate that in all &#8230; <a href="http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon</title>
		<link>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon</link>
		<comments>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12years]]></category>
		<category><![CDATA[AbVie]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bandwagon]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[joining]]></category>
		<category><![CDATA[LG]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2164</guid>
		<description><![CDATA[Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job &#8230; <a href="http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Ghost Keeps Haunting: NCD Dogs Cancer in &#8216;Compulsory License&#8217; Debate of India</title>
		<link>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india</link>
		<comments>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/#comments</comments>
		<pubDate>Mon, 11 Mar 2013 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Citizens']]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[collective]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[dogs]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[ghost]]></category>
		<category><![CDATA[haunting]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[keeps]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[protein]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treat]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[used]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2037</guid>
		<description><![CDATA[In November 2012, as a part of the ‘Campaign for Affordable Trastuzumab’ for the treatment of breast cancer, a citizens’ collective, reportedly sent an ‘Open Letter’ signed by around 200 cancer survivors, women’s groups, human rights and health rights campaigns &#8230; <a href="http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drugs’ Pricing: Apprehensive Voices Could Turn into a Self-Defeating Prophecy</title>
		<link>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy</link>
		<comments>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/#comments</comments>
		<pubDate>Mon, 04 Mar 2013 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[apprehensive]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CIPI]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[FICCI]]></category>
		<category><![CDATA[FOPE]]></category>
		<category><![CDATA[gandhi]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[IDMA]]></category>
		<category><![CDATA[IIT]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[Kharagpur]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NewZealand]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[PCPD]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[rajiv]]></category>
		<category><![CDATA[ratio]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2016</guid>
		<description><![CDATA[On February 21, 2013, the Department of Pharmaceuticals in a communication to the stakeholders announced that the committee to examine the issues of ‘Price Negotiations for Patented Drugs’ has since submitted its report to the Department. Simultaneously the stakeholders were &#8230; <a href="http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drugs-pricing-apprehensive-voices-could-turn-into-a-self-defeating-prophecy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
